Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives

The addition of trastuzumab to the treatment of a subset of patients with advanced gastric and gastroesophageal junction cancers showing HER2 positivity has been shown to confer clinical benefit; however, questions remain over the optimal methods for defining and selecting such patients. This review...

Descripción completa

Detalles Bibliográficos
Autores principales: Davidson, Michael, Starling, Naureen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135398/
https://www.ncbi.nlm.nih.gov/pubmed/27932891
http://dx.doi.org/10.2147/OTT.S100643
_version_ 1782471580935258112
author Davidson, Michael
Starling, Naureen
author_facet Davidson, Michael
Starling, Naureen
author_sort Davidson, Michael
collection PubMed
description The addition of trastuzumab to the treatment of a subset of patients with advanced gastric and gastroesophageal junction cancers showing HER2 positivity has been shown to confer clinical benefit; however, questions remain over the optimal methods for defining and selecting such patients. This review provides an overview of current standards for assessing HER2 positivity, the evolving treatment landscape for HER2-positive gastric and esophageal cancers and the challenges and potential future directions in optimal patient selection for HER2-targeted therapy.
format Online
Article
Text
id pubmed-5135398
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-51353982016-12-08 Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives Davidson, Michael Starling, Naureen Onco Targets Ther Review The addition of trastuzumab to the treatment of a subset of patients with advanced gastric and gastroesophageal junction cancers showing HER2 positivity has been shown to confer clinical benefit; however, questions remain over the optimal methods for defining and selecting such patients. This review provides an overview of current standards for assessing HER2 positivity, the evolving treatment landscape for HER2-positive gastric and esophageal cancers and the challenges and potential future directions in optimal patient selection for HER2-targeted therapy. Dove Medical Press 2016-11-25 /pmc/articles/PMC5135398/ /pubmed/27932891 http://dx.doi.org/10.2147/OTT.S100643 Text en © 2016 Davidson and Starling. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Davidson, Michael
Starling, Naureen
Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives
title Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives
title_full Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives
title_fullStr Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives
title_full_unstemmed Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives
title_short Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives
title_sort trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135398/
https://www.ncbi.nlm.nih.gov/pubmed/27932891
http://dx.doi.org/10.2147/OTT.S100643
work_keys_str_mv AT davidsonmichael trastuzumabinthemanagementofgastroesophagealcancerpatientselectionandperspectives
AT starlingnaureen trastuzumabinthemanagementofgastroesophagealcancerpatientselectionandperspectives

Ejemplares similares